Interleukin-6 induced synaptic dysgenesis in wild type vs. Shank3 mice
Project Number1R03MH138839-01
Contact PI/Project LeaderLEVISON, STEVEN W
Awardee OrganizationRUTGERS BIOMEDICAL AND HEALTH SCIENCES
Description
Abstract Text
ASD is a considered to be the result of complex interactions among genetic and environmental factors,
suggesting that the rising incidence of ASD in the past decades can be largely attributed to
environmental insults such as maternal infections. However, research using animal models for autism
have individually focused on either genetic mutations, pharmacological disruptors or immune activation.
The goal of this application is to develop a novel dual-hit mouse model to study gene x
environment interactions. Our studies will test the hypothesis that a short increase in the hub
cytokine IL-6 during a critical period of neural development will exacerbate the behavioral and
synaptic phenotypes in a genetic model of ASD. For these studies we will inject IL-6 into neonatal
heterozygous Shank3Δ4-22 mice. While the Shank3Δ4-22 homozygous mice have a penetrant
phenotype, the heterozygous mice have only a mild sociability phenotype. Our experiments will test the
hypothesis that modestly elevating IL-6 will exacerbate the behavioral and synaptic phenotypes of this
genetic model of ASD. Shank3Δ4-22 mice will be administered either PBS or 40 ng rmIL-6 twice daily
from P3-P7. We will evaluate male mice as juveniles and as young adults for those core behaviors
relevant to ASD (sociability, repetitive behavior, and communication). To assess more complex
behaviors the mice will be evaluated using the paired associates learning (PAL) task to evaluate spatial
memory, attention and response control, the Barnes Maze, the passive avoidance test to measure
avoidance memory and the elevated plus maze to assess anxiety. In Aim 2 we will evaluate the levels
of astrocyte-produced proteins that are known to regulate synaptogenesis at P21 and levels of
glutamate receptors and glutamate handling proteins. Additional work will evaluate dendritic complexity,
spine numbers, spine types and perineuronal nets in the dorsal hippocampus and prefrontal cortex. We
anticipate that upon completing these studies, that we will have established a novel dual-hit model for
ASD allowing us to gain new insights into gene x environment interactions that are remarkably
understudied in the context of autism. This new model will provide conceptual advancements for how
gene mutations important for ASD and inflammatory cytokines intersect to affect neuronal maturation
and synaptogenesis. The etiology of high functioning ASD, which affects over 40% of people with ASD,
remains enigmatic and lacks a relevant animal model. Therefore, we predict that this new dual hit model
will be widely adopted by ASD researchers to enable them to identify and test therapeutics for their
ability to decrease the penetrance of the negative aspects of ASD while preserving cognitive function.
Public Health Relevance Statement
Research using animal models for autism have individually focused on either genetic
mutations, pharmacological disruptors or immune activation. The goal of this application
is to develop a novel dual-hit mouse model to study gene x environment interactions.
Our studies will test the hypothesis that a short increase in the hub cytokine IL-6 during
a critical period of neural development will produce robust behavioral and synaptic
changes in heterozygous Shank3Δ4-22 mice, which otherwise have only a mild
sociability phenotype.
No Sub Projects information available for 1R03MH138839-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R03MH138839-01
Patents
No Patents information available for 1R03MH138839-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R03MH138839-01
Clinical Studies
No Clinical Studies information available for 1R03MH138839-01
News and More
Related News Releases
No news release information available for 1R03MH138839-01
History
No Historical information available for 1R03MH138839-01
Similar Projects
No Similar Projects information available for 1R03MH138839-01